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societal perspective, CK costs $8,400/ QALY compared to surgery; CK remained
dominant versus IMRT and PT. Results were most sensitive to cost of CK and
surgery, and utility weights for GU and SD. CONCLUSIONS: CyberKnife was found
to be cost-effective versus surgery, and resulted in cost savings and improved
quality-adjusted survival compared to radiation options for the treatment of local-
ized PC.
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OBJECTIVES: Each year in Brazil, 42.3% of all inpatients present skin ulcers during
the hospitalization period. Current clinical practice guidelines have not established
a gold standard protocol of care for pressure ulcers. Thus, this study aimed to
develop cost-effectiveness analysis comparing three different dressings: hydrocol-
loid, silver sulfadiazine 1% cream (SSD) and saline gauze (SG), under the perspec-
tive of Brazilian public hospitals. METHODS: The mean time to healing (MTH) for
each protocol was obtained from systematic reviews. Data from the Brazilian Hos-
pital Information System from January 1st to December 31st 2009 was used to
define the annual number of hospital admissions due to pressure ulcers (only
non-surgical records with L89 ICD-10 code were included). The model assumed
that SG is the current practice in Brazilian public hospitals and patients are dis-
charged at the time their wound heals. The difference in MHT was applied to the
average length of stay (LOS) reported in the database. Resource use was estimated
through expert panel andunit costswere obtained fromBrazilian official price lists.
RESULTS: 934 hospitalizations were identified with mean LOS of 13.72 days. Hy-
drocolloid and SSD would reduce the MHT in 4.72 and 2.72 days, thus reducing
patients’ LOS. The cost per change was estimated as 15.52BRL, 43.20BRL and
15.72BRL and the cost per protocol per patient (daily room charges and dressing
changes) was 902.50BRL, 559.61BRL and 907.99BRL, for SG, hydrocolloid and SSD,
respectively. Adopting hydrocolloid as wound management protocol would save
342.89BRL per patient and -BRL320,259 for the 2009 cohort. SSD projected savings
was 5.49BRL per patient and -BRL5,125.79 for the entire cohort. CONCLUSIONS:
Hydrocolloid dressing has shown higher efficacy when compared to SG or SSD
dressings, with fewer costs. The clinical and economic incremental results be-
tween different dressings reinforce the need of evidence-based decision making
and rational resource allocation.
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OBJECTIVES: Congenital hypothyroidism (CH) is a serious conditions and expen-
sive illness. The purpose of this study was to develop an economic model in order
to evaluate the cost-effectiveness ratios between two heel lancet devices in terms
success of the procedure in neonates undergoing the newborn screening test at the
Social Security Mexican Institute (IMSS) from the health care payer’s perspective.
METHODS: A cost-effectiveness analysis was developed using a decision-tree
model. Themodel simulates costs and effectiveness outcomes in a 15 years period.
The comparators were: Heel lance BD Safety-Flow lancet® and the BD QuikHeel
lancet®. The effectiveness measure was the number of cases of severe congenital
hypothyroidism avoided at the end of the follow-up period. Effectiveness data and
transition probabilities were taken from international published literature. The
estimation of resource use was performed employing local expert opinion surveys.
Cost and effectiveness were discounted 5% annually. The model was calibrated
according to international pharmacoeconomics guidelines. One-way and probabi-
listic sensitivity analyses were performed using Monte Carlo Simulation second-
order approach. RESULTS: Regarding effectiveness, the lancet Contact Activated
would prevent 75% of patients with CH detected in advanced stages and with the
use of the lancet Quickheel the percentage would increase to 98%, preventing 23%
more cases of severe CH. Themean cost per newborn screened in case of using the
lancet type would Contact Activated $12.2 and with the lancet Quikheel type
$11.71. The potential savings from the use of the lancet Quikheel would be around
$779,545.75 in the hold program. CONCLUSIONS:With these data we can conclude
that the use of the lancet Quikheel type is the best alternative, as it offers better
results at lower cost. In Mexico the use of the lancet Quikheel brings significant
clinical and economic benefits that make of the neonatal screening program a
better one.
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OBJECTIVES:Diabetes is a growing cause of death andmorbidity inmiddle-income
countries carrying a large financial burden for health systems. In recent years,
diabetes screening practices in Colombia have shifted from using the fasting glu-
cose test (FGT) towards relying on glycosylated hemoglobin (HbA1c) as physicians
consider it a more reliable tool to early detect diabetes. This analysis assesses the
cost-effectiveness of alternative screening strategies in general population in Co-
lombia from a health system perspective. METHODS: A decision-analytic model
was designed to compare four strategies: (1) FGT  confirmatory FGT (standard
practice); (2) FGT confirmatory HbA1c; (3) Only HbA1c and (4) no screening. Long-
term health outcomes (life years) and cost-outcomes were modeled via a 20-year
Markov model with three diabetes states: non-complicated, complicated diabetes
and death. Parameter values were based on data from the National Health Survey
and from the Ministry of Social Protection on general population. The model pro-
jectionswere comparable to those published elsewhere using CORE andColombian
literature on diabetes costs. One-way sensitivity analysis on the HbA1c cost was
also performed. RESULTS: No significant differences on costs per life-year saved
were found when comparing FGT  confirmatory FGT ($1,047) and FGT  confir-
matory HbA1c ($1,069) against no-screening. However, the use of only HbA1c was
associated with a higher cost per life-year saved ($2,455.93) when comparing
against no-screening. This result was mainly driven by not using a confirmatory
test rather than by the test itself. CONCLUSIONS: This analysis found the perfor-
mance of FGT confirmatory FGT and FGT confirmatory HbA1c to be similar and
highly cost-effective in general population older than 45when in comparison to no
screening. This finding has implications in both clinical and healthcare policymak-
ers in Colombia and in other Latin American countries with similar diabetes prev-
alence and treatment options.
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OBJECTIVES: The primary analysis of this study was to estimate the cost-effective-
ness of TAVI compared to standard management (SM) in inoperable patients with
severe, symptomatic aortic valve stenosis (SSAVS). The secondary analysis was to
preliminarily explore both the cost-effectiveness and value of information of TAVI
compared to surgical aortic valve replacement (SAVR) in operable patients at high
surgical risk with SSAVS.METHODS: A combined decision tree and Markov model
was developed to compare the costs, life-years (LYs) and quality-adjusted life-
years (QALYs) of TAVI (transfemoral (TF) and transapical (TA) approaches) to SM
and SAVR over a 5-year time horizon. This evaluation was conducted from a third
party payer’s perspective. RESULTS: In the primary analysis, comparing TF and SM
resulted in an incremental cost-effectiveness ratio (ICER) of $126,874/LY and
$222,378/QALY. Comparing TA and SM resulted in an ICER of $262,672/LY and
$1,454,241/QALY. In the secondary analysis, TF and SAVRwere compared, resulting
in an ICER of $39,676/LY and $81,758/QALY. Comparing TA and SAVR resulted in an
ICER of $183,454/LY. TAwas dominated by SAVRwhen comparing QALYs. The total
expected value of perfect information (EVPI) was at a maximum with a value of
$6,928 at a WTP threshold of $80,000/QALY. The expected value of partial perfect
information (EVPPI) was highest for the 30-day clinical event rates when compared
to the EVPPI values for the 1-year, 2-year and 3-year clinical event rates.
CONCLUSIONS: This economic evaluation suggested that TAVI might not be a
cost-effective option for inoperable patients in comparison to SM. The secondary
analysis suggested that TAVI might be a cost effective option for operable patients
compared to SAVR. To reduce the uncertainty in our estimate it might be worth-
while to obtain empirical evidence related to clinical event rates occurring 30-days
post operation.
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OBJECTIVES:New technologies in screening and treatment of diabetic retinopathy
(DR) and diabetic macular edema (DME) have emerged recently. The goal of this
systemic literature review is to identify and compare critical gaps in the published
economic evaluation literatures for screenings and treatments strategies of
DR/DME. METHODS: A systematic literature search was conducted to identify lit-
erature in English from 1980-2010, using PubMed, Embase, NHS NICE EED, and Tuft
CEA Registry. Key terms included “diabetic retinopathy”, “diabetic macular
edema”, and relevant terms for economic evaluations. All studies related to eco-
nomic analysis and decisionmodeling were included. Studies that focused only on
cost or utility were excluded. RESULTS: 52 articles were identified and 33 were
excluded based on the pre-specified exclusion criteria. Of the remaining 19 studies,
nine (47%) focused on screening methods, six (32%)on diabetic care, and four (21%)
on DR/DME treatment. Among the included studies, 12 studies (63%) were cost-
effective analyses, and sight-years saved was the most frequently used endpoint.
Seven studies (37%) were cost-utility analyses. A broad range of decision-analytic
frameworks and health state descriptions were observed. Some only assigned util-
ity to blindness, not to diabetic patients whomay have impaired quality of life due
to vision loss. In addition, although DR/DME is a bilateral condition, most studies
did not clearly explain how cost, utility, and disease progression were modeled for
the second eye.CONCLUSIONS:This literature review identified a range of decision
analytic frameworks, health states definitions, and utility sources employed in
economic evaluations of screening and treatment of DR/DME. Future studies as-
sessing cost-effectiveness of new technologies should transparently address these
areas.
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